_________
false
פלוריסטם תרפיוטיקס אינק
2
381
PLURISTEM THERAPEUTICS INC
Corporation no:
C12337-2001
8544
Israel Securities Authority
Tel Aviv Stock Exchange
C003
(
Public
)
Reported via MAGNA:
10/07/2017
www.isa.gov.il
www.tase.co.il
Reference:
2017-02-072060
Time of broadcast:
13:52
13:50:53
Other Report or Announcement
Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
_________
Austria_Approval_for_CLI_final_isa.pdf
Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, Targeting Initiation at 40 Active Sites by the End of 2017
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
NASDAQ CM
Date of revision of form structure:
28/06/2017
Address:
Matam Park
5
,
Haifa
31905
ISRAEL
,
Tel:
074-7107171
,
Fax:
074-7107172
E-mail address:
Info@Pluristem.Com
Company site:
www.pluristem.com
Previous names of reporting entity:
Name of the Signatory:
Aberman Zalman
Position of Signatory in the reporting corporation:
Chairman Of The Board & CEO
Name of Employer Company:
Address:
Matam Park
20
,
Haifa
31905
Telephone:
074-7107171
Facsimile:
074-7107172
E-mail:
zami@pluristem.com
2